Floatz logo

Hepcortespenlisimut-L

Liver Cirrhosis

Immunitor LLCPhase 2Dormant
CCC
51/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
73/ 100

Competitive context

49 Active assets in the Liver Cirrhosis cohort.

Asset / SponsorPhaseRating
Rifaximin
Post Graduate Institute of Medical Education and Research, Chandigarh
Phase 4BBB
SIMVASTATIN
Chang Gung Memorial Hospital
Phase 4BBB
WARFARIN
Kafrelsheikh University
Phase 4BB
Entecavir
Third Affiliated Hospital, Sun Yat-Sen University
Phase 4BB
Thymosin-̑
Beijing Friendship Hospital
Phase 4BB

View all 50 →

Same molecule, other indications

Hepcortespenlisimut-L is also rated in:

HCCDormant
B
Indicative ·
62 / 100
View asset →
hepatocellular carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
liver cancerDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →